Daisuke Yonezawa, Minoru Yagi
Effect of a School-based Fluoride Mouth-rinsing Programme on Dental Caries
International dental journal
study evaluates firstline application pembrolizumab metastatic nonsmallcell lung cancer mnsclc head neck squamous cell cancer hnscc gastric cancer renal cell carcinoma utilizing european society medical oncology magnitude clinical benefit scale esmomcbs american society clinical oncology value framework ascovf analysis incorporates data pivotal keynote trials study systematically assessed clinical benefit pembrolizumab advanced solid malignancies nine randomized controlled trials one comprised two experimental arms data extraction primary sources conducted pubmed asco esmo publications utilizing esmomcbs ascovf forms evaluation focused clinical benefit toxicity bonus points discrepancies resolved consensus discussions nine firstline indications pembrolizumab received food drug administration approval metastatic solid tumors 2018 2023 notable distinctions esmomcbs grades revealed seven trials substantial clinical benefit grades 5 4 three moderate negligible benefit grades 3 1 bonus points primarily based tail curve allocated three trials overall survival one progressionfree survival one significant improvement quality life evaluation pembrolizumab across diverse cancers especially mnsclc hnscc revealed varied outcomes challenges clinical benefit interpretation assessment clinical benefit incorporating quantitative qualitative endpoints underscores need consider survivorship outcomes patient perspectives comprehensive understanding